Effects of acute systemic endothelin receptor blockade on cardiac electrophysiology in vivo

Journal of Cardiovascular Pharmacology

Volumn 44, Issue 5, 2004, Pages 564-570

  Gelzer, Anna R M ^a   Attmann, Tim ^b   Radicke, Dirk ^c   Nydam, Daryl ^a   Candinas, Reto ^d   Lutter, Georg ^b  

^a Department of Obstetrics Gynecology   (United States)

^b UNIVERSITY OF KIEL   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Blood pressure; BQ 123; Electrophysiology; Endothelin 1; Pig

Indexed keywords

CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN RECEPTOR ANTAGONIST;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; DRUG EFFECT; ELECTROPHYSIOLOGY; HEART ATRIOVENTRICULAR NODE; HEART RATE; HEMODYNAMICS; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; QRS COMPLEX; QT INTERVAL; SINUS NODE;

ANIMALS; ATRIAL FUNCTION; ATRIOVENTRICULAR NODE; BLOOD PRESSURE; BUNDLE OF HIS; CARDIAC PACING, ARTIFICIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ELECTRIC STIMULATION; ELECTROCARDIOGRAPHY; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; ENDOTHELIN-1; HEART RATE; HEART VENTRICLES; INFUSIONS, INTRAVENOUS; PEPTIDES, CYCLIC; RECEPTOR, ENDOTHELIN A; SINOATRIAL NODE; SWINE; TIME FACTORS; VENTRICULAR PRESSURE;

EID: 7444231482     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200411000-00008     Document Type: Article

References (53)

1. Zehender M, Faber T, Brunner M, et al. Acute myocardial ischemia and ventricular arrhythmias in the pathogenesis of sudden cardiac death in coronary disease. Z Kardiol. 2000;89(Suppl 3):13-23.
2. Barton M, Kiowski W. The therapeutic potential of endothelin receptor antagonists in cardiovascular disease. Curr Hypertens Rep. 2001;3:322-330.
3. Lerman A, Edwards BS, Hallett JW, et al. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med. 1991;325:997-1001.
4. Spieker LE, Noll G, Ruschitzka FT, et al. Endothelin A receptor antagonists in congestive heart failure: blocking the beast while leaving the beauty untouched? Heart Fail Rev. 2001;6:301-315.
5. Pernow J, Wang QD. Endothelin in myocardial ischaemia and reperfusion. Cardiovasc Res. 1997;33:518-526.
6. Stewart DJ, Kubac G, Costello KB, et al. Increased plasma endothelin-1 in the early hours of acute myocardial infarction. J Am Coll Cardiol. 1991;18:38-43.
7. Barton M, Luscher TF. Endothelin antagonists for hypertension and renal disease. Curr Opin Nephrol Hypertens. 1999;8:549-556.
8. Teerlink JR. The role of endothelin in the pathogenesis of heart failure. Curr Cardiol Rep. 2002;4:206-212.
9. Barton M, Haudenschild CC. Endothelium and atherogenesis: endothelial therapy revisited. J Cardiovasc Pharmacol. 2001;38(Suppl 2):S23-S25.
10. Agapitov AV, Haynes WG. Role of endothelin in cardiovascular disease. J Renin Angiotensin Aldosterone Syst. 2002;3:1-15.
11. Duru F, Barton M, Luscher TF, et al. Endothelin and cardiac arrhythmias: do endothelin antagonists have a therapeutic potential as antiarrhythmic drugs? Cardiovasc Res. 2001;49:272-280.
12. Ezra D, Goldstein RE, Czaja JF, et al. Lethal ischemia due to intracoronary endothelin in pigs. Am J Physiol. 1989;257:H339-H343.
13. Salvati P, Chierchia S, Dho L, et al. Proarrhythmic activity of intracoronary endothelin in dogs: relation to the site of administration and to changes in regional flow. J Cardiovasc Pharmacol. 1991;17:1007-1014.
14. Garjani A, Wainwright CL, Zeitlin IJ, et al. Effects of endothelin-1 and the ETA-receptor antagonist, BQ123, on ischemic arrhythmias in anesthetized rats. J Cardiovasc Pharmacol. 1995;25:634-642.
15. Merkely B, Geller L, Toth M, et al. Mechanism of endothelin-induced malignant ventricular arrhythmias in dogs. J Cardiovasc Pharmacol. 1998;31(Suppl 1):S437-S439.
16. Toth M, Solti F, Merkely B, et al. Ventricular tachycardias induced by intracoronary administration of endothelin-1 in dogs. J Cardiovasc Pharmacol. 1995;26(Suppl 3):S153-S155.
17. Yorikane R, Koike H. The arrhythmogenic action of endothelin in rats. Jpn J Pharmacol. 1990;53:259-263.
18. Yorikane R, Koike H, Miyake S. Electrophysiological effects of endothelin-1 on canine myocardial cells. J Cardiovasc Pharmacol. 1991;17(Suppl 7):S159-S162.
19. Yorikane R, Shiga H, Miyake S, et al. Evidence for direct arrhythmogenic action of endothelin. Biochem Biophys Res Commun. 1990;173:457-462.
20. Szabo T, Geller L, Merkely B, et al. Investigating the dual nature of endothelin-1: ischemia or direct arrhythmogenic effect? Life Sci. 2000;66: 2527-2541.
21. Becker R, Merkely B, Bauer A, et al. Ventricular arrhythmias induced by endothelin-1 or by acute ischemia: a comparative analysis using three-dimensional mapping. Cardiovasc Res. 2000;45:310-320.
22. Wang QD, Hemsen A, Li XS, et al. Local overflow and enhanced tissue content of endothelin following myocardial ischaemia and reperfusion in the pig: modulation by L-arginine. Cardiovasc Res. 1995;29: 44-49.
23. Hemsen A, Ahlborg G, Ottosson-Seeberger A, et al. Metabolism of big endothelin-1 (1-38) and (22-38) in the human circulation in relation to production of endothelin-1 (1-21). Regul Pept. 1995;55:287-297.
24. Ishikawa K, Fukami T, Nagase T, et al. Cyclic pentapeptide endothelin antagonists with high ETA selectivity. Potency- and solubility-enhancing modifications. J Med Chem. 1992;35:2139-2142.
25. Ihara M, Ishikawa K, Fukuroda T, et al. In vitro biological profile of a highly potent novel endothelin (ET) antagonist BQ-123 selective for the ETA receptor. J Cardiovasc Pharmacol. 1992;20(Suppl 12):S11-S14.
26. B-receptor-mediated effects of endothelin-1 and [Ala1,3,11,15] endothelin-1 by BQ-123 in the anaesthetized rat. Br J Pharmacol. 1992;107:912-918.
27. Grover GJ, Dzwonczyk S, Parham CS. The endothelin-1 receptor antagonist BQ-123 reduces infarct size in a canine model of coronary occlusion and reperfusion. Cardiovasc Res. 1993;27:1613-1618.
28. Peter MG, Davenport AP. Characterization of the endothelin receptor selective agonist, BQ3020 and antagonists BQ123, FR139317, BQ788, 50235, Ro462005 and bosentan in the heart. Br J Pharmacol. 1996;117: 455-462.
29. A receptor antagonism with BQ-123 blocks ET-1 induced forearm vasoconstriction and decreases peripheral vascular resistance in healthy men. Br J Pharmacol. 2001;134: 648-654.
30. Nohria A, Garrett L, Johnson W, et al. Endothelin-1 and vascular tone in subjects with atherogenic risk factors. Hypertension. 2003;42:43-48.
31. Zhu Y, Yang HT, Endoh M. Negative chronotropic and inotropic effects of endothelin isopeptides in mammalian cardiac muscle. Am J Physiol. 1997;273:H119-H127.
32. Kolettis TM, Kyriakides ZS, Leftheriotis D, et al. Electrophysiologic effects of endothelin receptor-A blockade in patients with coronary artery disease. J Interv Card Electrophysiol. 2003;8:173-179.
33. Sharif I, Kane KA, Wainwright CL. Endothelin and ischaemic arrhythmias - antiarrhythmic or arrhythmogenic? Cardiovasc Res. 1998;39:625-632.
34. Raschack M, Juchelka F, Rozek-Schaefer G. The endothelin-A antagonist LU 135 252 supresses ischemic ventricular extrasystoles and fibrillation in pigs and prevents hypoxic cellular decoupling. J Cardiovasc Pharmacol. 1998;31(Suppl 1):S145-S148.
35. Douglas SA, Nichols AJ, Feuerstein GZ, et al. SB 209670 inhibits the arrhythmogenic actions of endothelin-1 in the anesthetized dog. J Cardiovasc Pharmacol. 1998;31(Suppl 1):S99-102.
36. Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet. 1994;344:852-854.
37. Cowburn PJ, Cleland JG, McArthur JD, et al. Short-term haemodynamic effects of BQ-123, a selective endothelin ET(A)-receptor antagonist, in chronic heart failure. Lancet. 1998;352:201-202.
38. SAS/STAT. SAS/STAT On-line Doc: version 8, 8th ed. Cary, NC: SAS Institute Inc, 2000 (CD-ROM).
39. Haynes WG, Ferro CJ, O'Kane KP, et al. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation. 1996;93:1860-1870.
40. Kelly JJ, Whitworth JA. Endothelin-1 as a mediator in cardiovascular disease. Clin Exp Pharmacol Physiol 1999;26:158-161.
41. Saetrum Opgaard O, Tom B, de Vries R, et al. Inotropic effects of endothelin compared to noradrenaline in porcine myocardial trabeculae. J Cardiovasc Pharmacol. 2000;36(5 Suppl 1):S172-S175.
42. Saetrum Opgaard O, Moller S, de Vries R, et al. Positive inotropic responses mediated by endothelin ET(A) and ET(B) receptors in human myocardial trabeculae. Clin Sci (Lond). 2000;99:161-168.
43. Burrell KM, Molenaar P, Dawson PJ, et al. Contractile and arrhythmic effects of endothelin receptor agonists in human heart in vitro: blockade with SB 209670. J Pharmacol Exp Ther. 2000;292:449-459.
44. Onishi K, Ohno M, Little WC, et al. Endogenous endothelin-1 depresses left ventricular systolic and diastolic performance in congestive heart failure. J Pharmacol Exp Ther. 1999;288:1214-1222.
45. Goraca A. Negative chronotropic effect of endothelin-1 (ET-1) in the cardiac pacemaker tissue. J Physiol Pharmacol. 2003;54:53-63.
46. Ono K, Eto K, Sakamoto A, et al. Negative chronotropic effect of endothelin 1 mediated through ETA receptors in guinea pig atria. Circ Res. 1995;76:284-292.
47. Ono K, Masumiya H, Sakamoto A, et al. Electrophysiological analysis of the negative chronotropic effect of endothelin-1 in rabbit sinoatrial node cells. J Physiol. 2001;537:467-488.
48. Zhang Z, Li YL, Ho SY. Effects of endothelin on the electrical activity of sino-atrial pacemaker cells of rabbit. Sheng Li Xue Bao. 1996;48:53-58.
49. Wiesfeld AC, De Langen CD, Crijns HJ, et al. Rate-dependent effects of the class III antiarrhythmic drug almokalant on refractoriness in the pig. J Cardiovasc Pharmacol. 1996;27:594-600.
50. Pires LA, Huang SK, Wagshal AB, et al. Electrophysiological effects of propofol on the normal cardiac conduction system. Cardiology. 1996;87: 319-324.
51. Vago H, Soos P, Zima E, et al. The ET(A) receptor antagonist LU 135252 has no electrophysiological or anti-arrhythmic effects during myocardial ischaemia/reperfusion in dogs. Clin Sci (Lond). 2002;103(Suppl 48): 223S-227S.
52. Toth M, Solti F, Merkely B, et al. Bradycardia increases the arrhythmogenic effect of endothelin. J Cardiovasc Pharmacol. 1998:31 (Suppl 1):S431-S433.
53. Geller L, Merkely B, Szokodi I, et al. Electrophysiological effects of intrapericardial infusion of endothelin-1. Pacing Clin Electrophysiol. 1998;21:151-156.